Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Completes Genzyme Genetics Buy

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that it has completed its acquisition of Genzyme Genetics.

LabCorp paid $925 million in cash for the unit of Genzyme. The deal, which was announced in September, includes all of Genzyme Genetics' testing services, technology, intellectual property rights, and nine testing laboratories.

In 2009, Genzyme Genetics brought in revenues of about $371 million. The menu of services it provides includes maternal serum screening, prenatal diagnostics, carrier screening, and postnatal testing.

LabCorp said the acquisition has a net cash cost of around $795 million — net of expected income tax benefits, less acquisition-related expenses.

"Closing the acquisition of Genzyme Genetics firmly establishes LabCorp as the premier genetics and oncology laboratory in the United States and further strengthens LabCorp's leadership position in personalized medicine." David King, chairman and CEO of LabCorp, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.